The second reason comes from the observation that glioblastoma patients with IDH mutant tumors have prolonged survival compared to patients with IDH wildtype tumors and that there are now pharmacological inhibitors of the IDH mutant enzymes available that block 2-HG formation [10]. The gene discussed is IDH2; the disease is glioblastoma.